¼¼°èÀÇ ÆéŸÀ̵å Ä¡·á ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, À¯Çüº°, Á¦Á¶¾÷ü À¯Çüº°, Åõ¿© °æ·Îº°, ÇÕ¼º ±â¼úº°, Áö¿ªº° ºÎ¹® ¿¹Ãø(2025-2030³â)
Peptide Therapeutics Market Size, Share & Trends Analysis Report By Application, By Type, By Type of Manufacturer, By Route Of Administration, By Synthesis Technology, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1678678
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 153 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ÆéŸÀ̵å Ä¡·á ½ÃÀå ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ÆéŸÀ̵å Ä¡·á ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 2,602¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2025-2030³â±îÁö CAGR 10.77%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¾Ï ¹× ±âŸ »ýȰ ½À°üº´ÀÇ Ä¡·á·Î ÀÎÇØ ºÎÀÛ¿ëÀÌ Àû°í È¿À²ÀûÀ̰í Áï°¢ÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ÏÀÇ ÀÌȯÀ²ÀÌ »ó½ÂÇϰí Àֱ⠶§¹®¿¡ ´Ù¸¥ Ä¡·á ¼ö´ÜÀ̳ª Àúºñ¿ëÀÇ Ä¡·á ¿É¼ÇÀÇ ¸ð»ö°ú µµÀÔÀÌ ¿ä±¸µÇ°í ÀÖ¾î ½ÃÀåÀÇ °ßÀοªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °Ô´Ù°¡ ³ëÀÎ Áõ°¡´Â ¾ÏÀ̳ª ´ç´¢º´ µî ´ë»ó ÁúȯÀÇ ÀÌȯÀ²À» À¯¹ßÇÔÀ¸·Î½á ¼ÒºñÀÚ ±â¹ÝÀ» ³ÐÈú °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÆéŸÀ̵å Ä¡·á ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

±¹Á¦¾Ï ¿¬±¸±â°ü(GLOBOCAN 2020)ÀÇ º¸°í¼­¿¡ µû¸£¸é 2020³â¿¡ »õ·Ó°Ô Áø´ÜµÇ´Â ¾Ï ȯÀÚ´Â ¼¼°è¿¡¼­ 1,929¸¸ 2,789¸íÀ̾ú°í, ¾Ï¿¡ ÀÇÇÑ »ç¸ÁÀÚ ¼ö´Â 995¸¸ 8,133¸íÀ̾ú½À´Ï´Ù. °Ô´Ù°¡ ¾ÏÀÇ 5³â°£ À¯º´·üÀº ¼¼°è¿¡¼­ 5055¸¸ 287¸íÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2040³â¿¡´Â ¼¼°èÀÇ ½Å±Ô¾Ï ȯÀÚ¼ö´Â 2,888¸¸ 7,940¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú, ¼¼°è¿¡¼­ ¾Ï ¹ß»ý·üÀÌ ³ô¾ÆÁö´Â °ÍÀº ¿¹Ãø ±â°£ Áß ÆéŸÀ̵å Ä¡·áÀÇ °³¹ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù°í »ý°¢µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ È­Çпä¹ý°ú ¹æ»ç¼±¿ä¹ýÀÇ ¾Ç¿µÇâ¿¡ ´ëÇÑ ÀÇ·áÁ¦°ø¾÷ü¿Í ȯÀÚÀÇ ÀÇ½Ä Áõ°¡°¡ ÆéŸÀÌµå ±â¹ÝÀÇ ¾àÁ¦¿Í °°Àº ´ëü Ä¡·áÀÇ Á߽à Áõ°¡¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÆéŸÀ̵å Á¦Á¶ °øÁ¤ÀÇ ±â¼úÀû Áøº¸´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü¿Í °ø±Þ¾÷ü´Â ÀûÀº ½Ã°£°ú ÀÚº» ÅõÀÚ·Î È¿À²ÀûÀÎ ¾à¹° ºÐÀÚ¸¦ »ý»êÇϱâ À§ÇÑ ½Å±â¼úÀÇ Ã¤Åÿ¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. Á¤Á¦ ¹× ÀÚµ¿È­ ÇÁ·Î¼¼½ºÀÇ °³¼±, Æó±â¹°ÀÇ ¹ß»ýÀÌ ÀûÀº °Íµµ ½ÃÀå ¼ºÀåÀÇ Ãß°¡ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î AmgenÀº 2022³â 3¿ù ³ë½ºÄ³·Ñ¶óÀ̳ª ÁÖ È¦¸® ½ºÇÁ¸µ½º¿¡ ÃֽйÙÀÌ¿À Á¦Á¶ ½Ã¼³À» °ø½ÄÀûÀ¸·Î °³¼³ÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. 2025³â¿¡ °³¼³ ¿¹Á¤ÀÎ ÀÌ ½Ã¼³Àº ¾ÏÀ̳ª ½ÉÀ庴 µî ½É°¢ÇÑ Áúº´À» Ä¡·áÇÏ´Â AmgenÀÇ ÀǾàǰÀÇ ¼ºÀå¿¡ ´ëÀÀÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19ÀÇ ´ëÀ¯ÇàÀº Áø´Ü Áö¿¬, Ä¡·á °³ÀÔ, ¾Ï Ä¡·á¸¦ À§ÇÑ ºñ¿ë È¿°úÀûÀÎ Ä¡·á °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÓ»ó °Ë»çÀÇ ÀúÇØ µî ¾Ï Ä¡·á ½ºÆåÆ®·³¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¾Ï Ä¡·á¸¦ À§ÇÑ ÆéŸÀ̵å Ä¡·áµµ ¿¹¿Ü´Â ¾Æ´Õ´Ï´Ù. ±Þ¼º È£Èí °ï¶õ ÁõÈıº(ARDS) ¹× ÁßÁõ ±Þ¼º È£Èí±â °¨¿°À¸·Î ÀÎÇÑ ´Ù¸¥ È£Èí±â ÁúȯÀÇ Ä¡·á¸¦ À§ÇÑ 15°³ÀÇ ÇÕ¼º ÆéŸÀ̵å¿Í °°Àº 2020³â 5¿ù ÇöÀç COVID-19ÀÇ Ä¡·á¸¦ À§ÇÑ 21°³ÀÇ ÆéŸÀ̵å ÀǾàǰÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª ÇöÀç ¾ÏÀ̳ª ´ë»ç¼º Áúȯ µî¿¡¼­ÀÇ ÆéŸÀ̵å Ä¡·áÀÇ ½Ç¿ëÈ­´Â ¾à¹° ºÎÁ·°ú ¿î¿µ»óÀÇ ¹®Á¦, COVID-19 ÀÌ¿ÜÀÇ Ä¡·á¸¦ Æ÷ÇÔÇÑ ÀÓ»ó °Ë»çÀÇ ÁøÇà Áö¿¬¿¡ ÀÇÇØ ¹æÇصǰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2022³â 5¿ù, EVER Pharma´Â º¸¸£Å×Á¶¹ÓÀÌ ÁõÈļº °ñ¼öÁ¾°ú ¸ÇƲ ¼¼Æ÷ ¸²ÇÁÁ¾ÀÇ Ä¡·áÁ¦·Î¼­ EU Àü¿ª¿¡¼­ ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. Jakavi´Â À¯·´¿¡¼­ ½ºÅ×·ÎÀ̵å ÀúÇ×¼º ÀÌ½ÄÆí ´ë ¼÷ÁÖº´ ȯÀÚ¿¡°Ô ³Î¸® »ç¿ëµÉ ¼ö ÀÖ´Â ÃÖÃÊÀÇ JAK1/2 ¾ïÁ¦Á¦°¡ µË´Ï´Ù. 2021³â 9¿ù Nimble Therapeutics¿Í Incyte´Â »õ·Î¿î ÆéŸÀ̵å Ä¡·á¹ýÀ» ¹ß°ßÇϱâ À§ÇÑ Àü·«Àû °øµ¿ ¿¬±¸¸¦ ½ÃÀÛÇß½À´Ï´Ù.

ÆéŸÀ̵å Ä¡·á ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÆéŸÀ̵å Ä¡·á ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ÆéŸÀ̵å Ä¡·á ½ÃÀå : ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå ÆéŸÀ̵å Ä¡·á ½ÃÀå : À¯Çüº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå ÆéŸÀ̵å Ä¡·á ½ÃÀå : Á¦Á¶¾÷ü À¯Çüº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå ÆéŸÀ̵å Ä¡·á ½ÃÀå : ÇÕ¼º ±â¼úº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦8Àå ÆéŸÀ̵å Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦9Àå ÆéŸÀ̵å Ä¡·á ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå °á·Ð/ÁÖ¿ä Æ÷ÀÎÆ®/KoL ÅëÂû

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Peptide Therapeutics Market Growth & Trends:

The global peptide therapeutics market size is expected to reach USD 260.25 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 10.77% from 2025 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Peptide Therapeutics Market Variables, Trends, & Scope

Chapter 4. Peptide Therapeutics Market: By Application Estimates & Trend Analysis

Chapter 5. Peptide Therapeutics Market: Type Estimates & Trend Analysis

Chapter 6. Peptide Therapeutics Market: Type of Manufacturer Estimates & Trend Analysis

Chapter 7. Peptide Therapeutics Market: Synthesis Technology Estimates & Trend Analysis

Chapter 8. Peptide Therapeutics Market: Route of Administration Estimates & Trend Analysis

Chapter 9. Peptide Therapeutics Market: Regional Estimates & Trend Analysis

Chapter 10. Competitive Landscape

Chapter 11. Conclusion/Key Takeaways/KoL Insights

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â